Literature DB >> 19139189

Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness.

Danielle I Stanisic1, Jack S Richards, Fiona J McCallum, Pascal Michon, Christopher L King, Sonja Schoepflin, Paul R Gilson, Vincent J Murphy, Robin F Anders, Ivo Mueller, James G Beeson.   

Abstract

Substantial evidence indicates that antibodies to Plasmodium falciparum merozoite antigens play a role in protection from malaria, although the precise targets and mechanisms mediating immunity remain unclear. Different malaria antigens induce distinct immunoglobulin G (IgG) subclass responses, but the importance of different responses in protective immunity from malaria is not known and the factors determining subclass responses in vivo are poorly understood. We examined IgG and IgG subclass responses to the merozoite antigens MSP1-19 (the 19-kDa C-terminal region of merozoite surface protein 1), MSP2 (merozoite surface protein 2), and AMA-1 (apical membrane antigen 1), including different polymorphic variants of these antigens, in a longitudinal cohort of children in Papua New Guinea. IgG1 and IgG3 were the predominant subclasses of antibodies to each antigen, and all antibody responses increased in association with age and exposure without evidence of increasing polarization toward one subclass. The profiles of IgG subclasses differed somewhat for different alleles of MSP2 but not for different variants of AMA-1. Individuals did not appear to have a propensity to make a specific subclass response irrespective of the antigen. Instead, data suggest that subclass responses to each antigen are generated independently among individuals and that antigen properties, rather than host factors, are the major determinants of IgG subclass responses. High levels of AMA-1-specific IgG3 and MSP1-19-specific IgG1 were strongly predictive of a reduced risk of symptomatic malaria and high-density P. falciparum infections. However, no antibody response was significantly associated with protection from parasitization per se. Our findings have major implications for understanding human immunity and for malaria vaccine development and evaluation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19139189      PMCID: PMC2643653          DOI: 10.1128/IAI.01129-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity.

Authors:  H Bouharoun-Tayoun; P Druilhe
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

2.  Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes.

Authors:  R G Bredius; C A Fijen; M De Haas; E J Kuijper; R S Weening; J G Van de Winkel; T A Out
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

3.  Relationship between humoral response to Plasmodium falciparum merozoite surface antigen-2 and malaria morbidity in a highly endemic area of Papua New Guinea.

Authors:  F al-Yaman; B Genton; R F Anders; M Falk; T Triglia; D Lewis; J Hii; H P Beck; M P Alpers
Journal:  Am J Trop Med Hyg       Date:  1994-11       Impact factor: 2.345

4.  Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.

Authors:  A F Egan; J Morris; G Barnish; S Allen; B M Greenwood; D C Kaslow; A A Holder; E M Riley
Journal:  J Infect Dis       Date:  1996-03       Impact factor: 5.226

5.  Enhanced Plasmodium falciparum merozoite phagocytosis by monocytes from immune individuals.

Authors:  S Khusmith; P Druilhe; M Gentilini
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

6.  Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass.

Authors:  R R Taylor; D B Smith; V J Robinson; J S McBride; E M Riley
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

7.  Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans.

Authors:  David T McNamara; Jodi M Thomson; Laurin J Kasehagen; Peter A Zimmerman
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

8.  Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum.

Authors:  Julie Healer; Vince Murphy; Anthony N Hodder; Rosella Masciantonio; Alan W Gemmill; Robin F Anders; Alan F Cowman; Adrian Batchelor
Journal:  Mol Microbiol       Date:  2004-04       Impact factor: 3.501

9.  Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes.

Authors:  H Bouharoun-Tayoun; P Attanath; A Sabchareon; T Chongsuphajaisiddhi; P Druilhe
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

10.  Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum.

Authors:  A F Egan; J A Chappel; P A Burghaus; J S Morris; J S McBride; A A Holder; D C Kaslow; E M Riley
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

View more
  139 in total

1.  Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children.

Authors:  Carlota Dobaño; Diana Quelhas; Llorenç Quintó; Laura Puyol; Elisa Serra-Casas; Alfredo Mayor; Tacilta Nhampossa; Eusebio Macete; Pedro Aide; Inacio Mandomando; Sergi Sanz; Sanjeev K Puniya; Bijender Singh; Puneet Gupta; Arindam Bhattacharya; Virander S Chauhan; John J Aponte; Chetan E Chitnis; Pedro L Alonso; Clara Menéndez
Journal:  Clin Vaccine Immunol       Date:  2011-12-14

2.  Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized.

Authors:  Kazutoyo Miura; Hong Zhou; Ababacar Diouf; Gregory Tullo; Samuel E Moretz; Joan A Aebig; Michael P Fay; Louis H Miller; Ogobara K Doumbo; Issaka Sagara; Alassane Dicko; Carole A Long; Ruth D Ellis
Journal:  Vaccine       Date:  2011-01-31       Impact factor: 3.641

3.  Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies.

Authors:  Janine Stubbs; Sope Olugbile; Balam Saidou; Jacques Simpore; Giampietro Corradin; Antonio Lanzavecchia
Journal:  Infect Immun       Date:  2010-12-28       Impact factor: 3.441

4.  Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.

Authors:  Karen S Harris; Christopher G Adda; Madhavi Khore; Damien R Drew; Antonina Valentini-Gatt; Freya J I Fowkes; James G Beeson; Sheetij Dutta; Robin F Anders; Michael Foley
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

5.  Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria.

Authors:  Matthew B McCarra; George Ayodo; Peter O Sumba; James W Kazura; Ann M Moormann; David L Narum; Chandy C John
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

6.  Multiplex bead assay for serum samples from children in Haiti enrolled in a drug study for the treatment of lymphatic filariasis.

Authors:  Delynn M Moss; Jeffrey W Priest; Alexis Boyd; Tiffany Weinkopff; Zuzana Kucerova; Michael J Beach; Patrick J Lammie
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

7.  Inclusion of the murine IgGκ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.

Authors:  Jairo A Fonseca; Jessica N McCaffery; Juan Caceres; Elena Kashentseva; Balwan Singh; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  Vaccine       Date:  2018-04-12       Impact factor: 3.641

8.  Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children.

Authors:  Jennifer L Cole-Tobian; Pascal Michon; Moses Biasor; Jack S Richards; James G Beeson; Ivo Mueller; Christopher L King
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

9.  Sequential processing of merozoite surface proteins during and after erythrocyte invasion by Plasmodium falciparum.

Authors:  Michelle J Boyle; Christine Langer; Jo-Anne Chan; Anthony N Hodder; Ross L Coppel; Robin F Anders; James G Beeson
Journal:  Infect Immun       Date:  2013-11-11       Impact factor: 3.441

10.  Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites.

Authors:  Ann M Moormann; Peter Odada Sumba; Kiprotich Chelimo; Hua Fang; Daniel J Tisch; Arlene E Dent; Chandy C John; Carole A Long; John Vulule; James W Kazura
Journal:  J Infect Dis       Date:  2013-03-28       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.